Combinations of agents have replaced sunitinib as first-line therapy for advanced renal-cell cancer. Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their best practices for helping patients get the most benefit out of combination therapy for their advanced renal-cell cancer diagnosis.
Related Items
Videos published on December 19, 2023 in Interview with the Innovators
Videos published on December 18, 2023 in Interview with the Innovators
Videos published on November 27, 2023 in Interview with the Innovators
Videos published on November 27, 2023 in Interview with the Innovators
Videos published on November 27, 2023 in Interview with the Innovators
Videos published on November 27, 2023 in Interview with the Innovators
Videos published on November 27, 2023 in Interview with the Innovators
Videos published on October 8, 2021 in Interview with the Innovators
Videos published on September 24, 2021 in Interview with the Innovators
Videos published on September 8, 2021 in Interview with the Innovators